Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan

BACKGROUND: Pembrolizumab is currently approved as a first-line therapy for advanced non-small cell lung cancer (NSCLC) patients with a programed death ligand-1 (PD-L1) expression ≥50%. However, the association between the efficacy of pembrolizumab and PD-L1 expression levels in patients with PD-L1...

Descripción completa

Detalles Bibliográficos
Autores principales: Edahiro, Ryuya, Kanazu, Masaki, Kurebe, Hiroyuki, Mori, Masahide, Fujimoto, Daichi, Taniguchi, Yoshihiko, Suzuki, Hidekazu, Hirano, Katsuya, Yokoyama, Toshihide, Morita, Mitsunori, Fukuda, Yasushi, Uchida, Junji, Makio, Takeshi, Tamiya, Motohiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668842/
https://www.ncbi.nlm.nih.gov/pubmed/31365588
http://dx.doi.org/10.1371/journal.pone.0220570

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668842/
https://www.ncbi.nlm.nih.gov/pubmed/31365588
http://dx.doi.org/10.1371/journal.pone.0220570

Ejemplares similares